VK

Vineet Kela

Active Director Director DIN 01042495
DIN 01042495 First appointment May 1998 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 5 active board seats
Past companies 1 historical roles
Total affiliations 6 Since May 1998
Shareholding value •••• Premium profile

About Vineet Kela

Data last updated:

Vineet Kela is a Director at Swaroop Pharmaceuticals Private Limited (since 1998), Director at Man Safe Health Care Devices Private Limited (since 2013) and Director at Subh Parenteral Private Limited (since 2021), and holds 2 more current directorships. The companies operate in Pharma, Chemicals and Healthcare. The 3 current companies with reported revenue have a combined latest revenue of ₹82.30 Cr; the largest is Swaroop Pharmaceuticals Private Limited at ₹82.25 Cr (FY 2022). Earlier, Vineet Kela was a Director at Swaroop Consultancy Services Private Limited (from 2011).

DIN 01042495
Primary Designation Director
Industry Pharma
First Appointment 08 May 1998
Oldest Company Age 28 yrs
Largest company Swaroop Pharmaceuticals Private Limited · ₹82.25 Cr (FY 2022)
Combined revenue ₹82.30 Cr across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director08 May 19981998₹82.25 Cr (FY 2022)Active
Director31 Oct 20132008₹4.2 Lakh (FY 2025)Active
Subh Parenteral Private Limited U24233UP2021PTC141159
Director03 Feb 20212021₹77,178 (FY 2023)Active
Director28 May 20242024Active
Swaroop Films Private Limited U22110MH2010PTC203269
Director15 May 20102010Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director29 Mar 20112011Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Swaroop Films Private Limited
Swaroop Pharmaceuticals Private Limited
Subh Parenteral Private Limited
Swaroop Consultancy Services Private Limited
Premium access

Shareholding and investment profile for Vineet Kela

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vineet Kela

Vineet Kela currently holds 5 directorships: Swaroop Pharmaceuticals Private Limited (Director, since 08 May 1998, revenue ₹82.25 Cr (FY 2022)); Man Safe Health Care Devices Private Limited (Director, since 31 Oct 2013, revenue ₹4.2 Lakh (FY 2025)); Subh Parenteral Private Limited (Director, since 03 Feb 2021, revenue ₹77,178 (FY 2023)); Vamkg Pharmaceuticals Private Limited (Director, since 28 May 2024); Swaroop Films Private Limited (Director, since 15 May 2010).

Vineet Kela was first appointed on 08 May 1998 as Director at Swaroop Pharmaceuticals Private Limited. The most recent appointment on record is 28 May 2024 at Vamkg Pharmaceuticals Private Limited.

The 3 current companies of Vineet Kela that report revenue have a combined latest revenue of ₹82.30 Cr: Swaroop Pharmaceuticals Private Limited ₹82.25 Cr (FY 2022); Man Safe Health Care Devices Private Limited ₹4.2 Lakh (FY 2025); Subh Parenteral Private Limited ₹77,178 (FY 2023).

Vineet Kela held 1 earlier board appointment: Swaroop Consultancy Services Private Limited (Director, from 29 Mar 2011).

The current boards of Vineet Kela's companies include Atul Agrawal (Swaroop Pharmaceuticals Private Limited), Jaiprakash Agarwal (Swaroop Pharmaceuticals Private Limited), Puneet Kela (Swaroop Pharmaceuticals Private Limited), Sanjay Maheshwari (Swaroop Pharmaceuticals Private Limited), Vijay Maheshwari (Swaroop Pharmaceuticals Private Limited), Arun Singh (Subh Parenteral Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available